Literature DB >> 29274768

Evaluation of the impact of hearing loss in adults: Validation of a quality of life questionnaire.

E Ambert-Dahan1, C Laouénan2, M Lebredonchel3, S Borel1, C Carillo3, D Bouccara1, O Sterkers1, E Ferrary1, I Mosnier4.   

Abstract

OBJECTIVES: The impact of hearing loss and of auditory rehabilitation (hearing aid, cochlear implant) on quality of life is a crucial issue. Commonly used questionnaires to assess quality of life in these patients (Nijmegen, APHAB, GBI) are time-consuming, difficult for patients to fill out, and show poor sensitivity to small improvements or deterioration. The objective of the present study was to validate a dedicated quality of life scale for hearing-impaired adults with or without auditory rehabilitation.
MATERIAL AND METHODS: ERSA (Évaluation du Retentissement de la Surdité chez l'Adulte: Evaluation of the Impact of Hearing Loss in Adults) is a self-administered questionnaire. It is divided into 4 domains, each comprising 5 questions graded from 1 to 10. The questions are simple, and formulated so patients will answer according to how they feel at the actual time of the session. Test-retest reliability was measured in 38 patients. Internal coherence and validity against the APHAB questionnaire as gold standard and in relation to hearing performance were measured in 122 patients at auditory assessment. Sensitivity to change in hearing was measured in 36 cochlear implant patients, before and 6 or 12 months after implantation.
RESULTS: Test-retest reliability was very satisfactory (ρ=0.88). Internal coherence was good for all questions. External validity, comparing ERSA to APHAB scores in the same non-implanted hearing-impaired patients, was good (ρ=0.52). Additionally, ERSA scores correlated with hearing performance in adverse conditions (monosyllabic words: ρ=0.22; sentences in noise: ρ=0.19). In patients tested before and after cochlear implantation, improvement in hearing performance in silence and in noise correlated with an improvement in ERSA score (ρ=0.37 to 0.59, depending on the test), but not to GBI score.
CONCLUSION: The ERSA questionnaire is easy and quick to use, reliable, and sensitive to change in hearing performance after cochlear implantation.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Auditory rehabilitation; Cochlear implant; Evaluation; Hearing loss

Mesh:

Year:  2017        PMID: 29274768     DOI: 10.1016/j.anorl.2017.09.003

Source DB:  PubMed          Journal:  Eur Ann Otorhinolaryngol Head Neck Dis        ISSN: 1879-7296            Impact factor:   2.080


  4 in total

1.  Best Practices in the Development, Translation, and Cultural Adaptation of Patient-Reported Outcome Measures for Adults With Hearing Impairment: Lessons From the Cochlear Implant Quality of Life Instruments.

Authors:  Ariane Laplante-Lévesque; Judy R Dubno; Isabelle Mosnier; Evelyne Ferrary; Theodore R McRackan
Journal:  Front Neurosci       Date:  2021-11-24       Impact factor: 4.677

Review 2.  Listening-Based Communication Ability in Adults With Hearing Loss: A Scoping Review of Existing Measures.

Authors:  Katie Neal; Catherine M McMahon; Sarah E Hughes; Isabelle Boisvert
Journal:  Front Psychol       Date:  2022-03-10

3.  Benefits of Cochlear Implantation in Middle-Aged and Older Adults.

Authors:  Christiane Völter; Lisa Götze; Imme Haubitz; Stefan Dazert; Jan Peter Thomas
Journal:  Clin Interv Aging       Date:  2020-09-07       Impact factor: 4.458

4.  Using Generic and Disease-Specific Measures to Assess Quality of Life before and after 12 Months of Hearing Implant Use: A Prospective, Longitudinal, Multicenter, Observational Clinical Study.

Authors:  Luis Lassaletta; Miryam Calvino; Isabel Sanchez-Cuadrado; Piotr Henryk Skarzynski; Katarzyna B Cywka; Natalia Czajka; Justyna Kutyba; Dayse Tavora-Vieira; Paul van de Heyning; Griet Mertens; Hinrich Staecker; Bryan Humphrey; Mario Zernotti; Maximo Zernotti; Astrid Magele; Marlene Ploder; Julia Speranza Zabeu
Journal:  Int J Environ Res Public Health       Date:  2022-02-22       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.